Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Raderer

Showing results (261-270 of 264) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 264 results.
ESMO Open|January 21, 2020
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignanciesBarbara Kiesewetter, Nathan I Cherny, Nicolas Boissel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
The Lancet. Oncology|August 26, 2017
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialMarianne E Pavel, Simron Singh, Jonathan R Strosberg, et al.
Cancer Discovery|October 12, 2021
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional RespondersChristoph Kornauth, Tea Pemovska, Gregory I Vladimer, et al.
Pageof 27

Showing results (261-270 of 264) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 264 results.
ESMO Open|January 21, 2020
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignanciesBarbara Kiesewetter, Nathan I Cherny, Nicolas Boissel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)Jaume Capdevila, Nicola Fazio, Carlos Lopez, et al.
The Lancet. Oncology|August 26, 2017
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialMarianne E Pavel, Simron Singh, Jonathan R Strosberg, et al.
Cancer Discovery|October 12, 2021
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional RespondersChristoph Kornauth, Tea Pemovska, Gregory I Vladimer, et al.
Pageof 27